Arecor Therapeutics plc (“Arecor” or the “Group”) ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY Arecor expands its global partnerships through collaboration to develop an enhanced antibody formulation Cambridge, UK, 17 August 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an agreement with a top 10 pharmaceutical company to develop an enhanced antibody formulation for one of its investigational drugs. Under the terms of this agreement, Arecor will use its…

Hello to all ON members, We are thrilled to announce that MedFlow Clinical has officially joined the prestigious ranks of One Nucleus. As a new member of this esteemed network, we eagerly anticipate the remarkable opportunities that lie ahead. Our team is excited to engage with the vibrant community of Life Science professionals within One Nucleus, and we are eagerly looking forward to forging meaningful connections, sharing insights, and collaborating on cutting-edge advancements in the field. Through this partnership, we are confident that MedFlow Clinical will contribute to, and benefit…

AMSBIO, a provider of cutting-edge products and services for accelerating stem cell research, has sponsored two aspiring life scientists to attend and present posters at the recent ISSCR 2023 conference in Boston, USA. Whilst the original award was for one researcher, AMSBIO doubled the fund and awarded two grants based on the high quality of the entries. Krystyna Joyce, AMSBIO’s marketing manager, said “The entries were so impressive that we ended up sponsoring two winners instead of one: Kerstin Filippi, a doctoral student at the University of Bonn researching in BAG3-associated muscle…

One Nucleus Partner, Agility Life Sciences, has announced a collaborative services agreement with Inaphaea BioLabs. Claire Thompson, CEO of Agility, commented: "This will enable our clients to take the next steps in their development programmes by testing their prototype formulations in the Inaphaea cell based studies. We believe this will be beneficial to both companies as well as to our clients, creating a more comprehensive scientific environment, and accelerating development timelines."

Progressive plans for the next phase of Manchester Science Park’s masterplan development have been approved by Manchester City Council. The scheme will see Bruntwood SciTech, a 50:50 joint venture between Bruntwood and Legal & General, deliver a £60m redevelopment of the Park’s existing Greenheys building, bringing forward 131,000 sq ft of highly specialist world-class lab space. The redevelopment by the UK’s leading property provider dedicated to the growth of the science and technology sector forms the third phase of Bruntwood SciTech’s masterplan to grow the science and technology hub…

Astex Expands Drug Discovery Collaboration With MSD Cambridge, UK, 8 August 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA).  The goal of the collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer. “Astex is applying its…

 If anyone UK-based missed out on a stand at Medica and would like a 12 sq m (3mx4m) shell stand on the UK (ABHI) pavilion in Hall 16, please get in touch with Berenice.Mann@clsdiagnostics.com. 

Manchester, 9th August, 2023 Kadans Science Partner has submitted a detailed planning application for a state-of-the-art life science building at Upper Brook Street. Working collectively with a consortium of partners, this significant development forms a key part of the transformative vision to deliver an exemplary new neighbourhood for the city.  The building consists of an expansive ground floor plus 7 upper floors. The lower portion of the building is oriented around a central atrium to provide informal break out zones and promote interdisciplinary collaboration. Through…

 Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately. Dr. Zamiri brings with her extensive experience in biopharmaceutical and small molecule drug discovery and development, drug and device safety, pharmacovigilance, and biomarker development across various therapeutic areas. Dr. Zamiri joins CTx from Graybug Vision, Inc., where she held the position of Chief Medical Officer and was…

Astex Expands Drug Discovery Collaboration With MSD Cambridge, UK, 8 August 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announced an exclusive worldwide research collaboration and license agreement with MSD (Merck & Co., Inc., Rahway, N.J., USA). The goal of the collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer. “Astex is applying its…